HANGZHOU, China, Sept. 3, 2024 /PRNewswire/ -- After winning the tenders from two giant Chinese companies – China International Water & Electric Corp. (CWE) and the Power Construction Corporation of China (POWERCHINA), a total of one gigawatt (GW) Astronergy n-type TOPCon solar modules will be shipped to Algeria to support the country's 2,000 MW solar plant construction plan.
The 2,000MW plan is a photovoltaic power plant construction plan proposed by Sonelgaz, Algeria's state-owned power utility. The plan is to build 15 solar power plants in the country's 12 provinces, each with a capacity ranging from 80 to 220 MW. Most of the solar projects in this plan are constructed by Chinese companies.
This time, Astronergy won six major projects, namely Abadla 80MW PV plant, Batemete 220MW PV plant, Gueltet Sidi Saad 200MW PV plant, Douar El Maa 200MW PV plant, Ouled Djellal 80MW PV plant, and Biskra 220MW PV plant projects, which will be constructed by CWE and POWERCHINA respectively.
Among these projects, the 220MW Biskra project is one of the largest in the 2,000MW plan, and its construction has already started. The project uses Astronergy's ASTRO N5 TOPCon solar modules.
According to local media reports, Algeria's Minister of Energy and Mining, Mohamed Alkab, said at the groundbreaking ceremony of the Biskra project that the construction of the project will not only create more than 600 jobs for the local community and promote economic development, but also has far-reaching significance for improving Algeria's energy structure and realising the energy transition strategy.
Upon completion, the project is expected to generate approximately 400 million kWh of clean electricity annually, equivalent to a reduction of 330,000 tonnes of carbon dioxide emissions.
As one of the competitive PV module suppliers in the industry, Africa is one of its important markets and also a place it is eager to join to support local energy transition process. The Noor Ouarzazate PV plant in Morocco, Benban solar plant in Egypt both have the supports of Astronergy solar modules.
In the face of the wave of global clean energy transition Astronergy will continue to work with its partners to support high reliability products to help all customers with green energy solutions for sustainable development.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
1GW Astronergy modules to boost solar utilization in Africa
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
